Dr. Hidalgo Discusses the Phase III TRYbeCA1 Trial in Pancreatic Cancer

Manuel Hidalgo, MD, PhD
Published: Tuesday, Nov 27, 2018



Manuel Hidalgo, MD, PhD, professor of medicine, Harvard Medical School, chief, Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the phase III TRYbeCA1 trial in patients with advanced pancreatic adenocarcinoma.

TRYbeCA1 (NCT03665441) is a randomized, international phase III trial evaluating whether the L-asparaginase-based therapy eryaspase (Graspa), in combination with chemotherapy can improve overall survival (OS) compared with chemotherapy alone. In addition to the primary endpoint of OS, secondary endpoints of this trial are progression-free survival, objective response rate, duration of response, and disease control rate.

Patients enrolled in the trial will receive eryaspase at a dose of 100 IU/kg administered intravenously 1 hour prior to chemotherapy every 2 weeks. Chemotherapy will be chosen based on the first-line chemotherapy that the patient was exposed to. If the patient has not received either an irinotecan-based chemotherapy or chemotherapy with gemcitabine and nab-paclitaxel (Abraxane), the physician may choose either regimen. Hidalgo says that this is a study that is flexible, as it is applicable to the majority of patients with advanced pancreatic adenocarcinoma.
SELECTED
LANGUAGE


Manuel Hidalgo, MD, PhD, professor of medicine, Harvard Medical School, chief, Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the phase III TRYbeCA1 trial in patients with advanced pancreatic adenocarcinoma.

TRYbeCA1 (NCT03665441) is a randomized, international phase III trial evaluating whether the L-asparaginase-based therapy eryaspase (Graspa), in combination with chemotherapy can improve overall survival (OS) compared with chemotherapy alone. In addition to the primary endpoint of OS, secondary endpoints of this trial are progression-free survival, objective response rate, duration of response, and disease control rate.

Patients enrolled in the trial will receive eryaspase at a dose of 100 IU/kg administered intravenously 1 hour prior to chemotherapy every 2 weeks. Chemotherapy will be chosen based on the first-line chemotherapy that the patient was exposed to. If the patient has not received either an irinotecan-based chemotherapy or chemotherapy with gemcitabine and nab-paclitaxel (Abraxane), the physician may choose either regimen. Hidalgo says that this is a study that is flexible, as it is applicable to the majority of patients with advanced pancreatic adenocarcinoma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x